Want to see DNA full AI Analyst Report?
DNA Stock Chart & Stats
$8.86
-$0.35(-3.13%)
At close: 4:00 PM EST
$8.86
-$0.35(-3.13%)
Day’s Range― - ―
52-Week Range$5.37 - $17.58
Previous CloseN/A
Volume618.97K
Average Volume (3M)1.08M
Market Cap
$516.72M
Enterprise Value$395.48
Total Cash (Recent Filing)$373.46M
Total Debt (Recent Filing)$410.70M
Price to Earnings (P/E)―
Beta2.95
Next Earnings
Aug 06, 2026EPS Estimate
-0.9Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.37
Shares Outstanding53,361,140
10 Day Avg. Volume1,030,563
30 Day Avg. Volume1,083,564
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.91
Price to Sales (P/S)2.71
P/FCF Ratio-2.58
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$12.00Price Target Upside35.44% Upside
Rating ConsensusHold
Number of Analyst Covering2
EPS Forecast (FY)-3.91
Revenue Forecast (FY)$105.65M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustained ~81% gross margins signal that Ginkgo's engineering platform and IP capture significant value versus direct costs. High gross margins provide structural leverage as revenue scales, enabling potential operating leverage and investment in automation and partnerships even while SG&A/R&D are reset.
Autonomous Lab Platform ScaleRapid rack expansion and high protocol throughput demonstrate meaningful scale in Ginkgo's autonomous lab asset base. Scale increases switching costs, creates data/network effects, and supports recurring-foundry economics that can convert automation advantages into durable service moat and longer-term revenue streams.
Stronger Liquidity And Cost DisciplineA $373M cash balance, zero bank debt and sizable Y/Y cost cuts afford runway to complete Nebula scale-up and commercial initiatives. Reaffirmed burn guidance and material expense reductions reduce near-term refinancing risk and give management time to translate platform gains into sustainable revenue.
Bears Say
Scaling And Commercial Conversion RiskOperational complexity in integrating devices, schedulers and debugging at scale creates durable execution risk. Early-stage channel and cloud offerings have uncertain monetization timelines; technical scaling issues can delay customer throughput and revenues, pressuring margins and ROI on automation investments.
Persistent Cash Burn And Rising LeverageOngoing negative operating and free cash flow coupled with a near 1.0 debt/equity trajectory mean the business remains reliant on external financing. Rising leverage reduces strategic flexibility, increases refinancing exposure, and constrains the pace at which Ginkgo can invest in commercialization without diluting stakeholders.
Sharp Revenue ContractionSustained and deep revenue declines weaken the operating leverage benefit of high gross margins. Falling top-line reduces ability to cover fixed automation and lab costs, delays milestone-triggered downstream economics, and heightens execution risk for converting platform scale into durable commercial growth.
Ginkgo Bioworks Holdings News
DNA FAQ
What was Ginkgo Bioworks Holdings, Inc.’s price range in the past 12 months?
Ginkgo Bioworks Holdings, Inc. lowest stock price was $5.37 and its highest was $17.58 in the past 12 months.
What is Ginkgo Bioworks Holdings, Inc.’s market cap?
Ginkgo Bioworks Holdings, Inc.’s market cap is $516.72M.
When is Ginkgo Bioworks Holdings, Inc.’s upcoming earnings report date?
Ginkgo Bioworks Holdings, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 16 days.
How were Ginkgo Bioworks Holdings, Inc.’s earnings last quarter?
Ginkgo Bioworks Holdings, Inc. released its earnings results on May 07, 2026. The company reported -$1.39 earnings per share for the quarter, missing the consensus estimate of -$1.211 by -$0.179.
Is Ginkgo Bioworks Holdings, Inc. overvalued?
According to Wall Street analysts Ginkgo Bioworks Holdings, Inc.’s price is currently Undervalued.
Does Ginkgo Bioworks Holdings, Inc. pay dividends?
Ginkgo Bioworks Holdings, Inc. does not currently pay dividends.
What is Ginkgo Bioworks Holdings, Inc.’s EPS estimate?
Ginkgo Bioworks Holdings, Inc.’s EPS estimate is -0.9.
How many shares outstanding does Ginkgo Bioworks Holdings, Inc. have?
Ginkgo Bioworks Holdings, Inc. has 53,361,140 shares outstanding.
What happened to Ginkgo Bioworks Holdings, Inc.’s price movement after its last earnings report?
Ginkgo Bioworks Holdings, Inc. reported an EPS of -$1.39 in its last earnings report, missing expectations of -$1.211. Following the earnings report the stock price went down -13.469%.
Which hedge fund is a major shareholder of Ginkgo Bioworks Holdings, Inc.?
Currently, no hedge funds are holding shares in DNA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ginkgo Bioworks Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$12.00 (35.44% Upside)
$12.00 (35.44% Upside)
Blogger Sentiment
Neutral
DNA Sentiment 50%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 201.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 1.4%
Last 30 Days ▲ 4.2%
Last 30 Days ▲ 4.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-25.46%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-20.13%
Trailing 12-Months
Company Description
Ginkgo Bioworks Holdings, Inc.
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products. It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats. In addition, the company offers genetic medicine R&D, protein engineering, bioprocess development, crop nutrition and protection solutions, and plant trait optimization. The company serves pharmaceutical and biotechnology, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
DNA Revenue Breakdown
57.08% Cell Engineering
42.92% Biosecurity
DNA Stock 12 Month Forecast
Average Price Target
$12.00
▲(35.44% Upside)
Technical Analysis
Niagen Bioscience
―
Monopar Therapeutics Inc
―
Lyell Immunopharma
―
Jade Biosciences
―
AbSci
―
Ownership Overview
2.94% Insiders
15.87% Mutual Funds
1.93% Other Institutional Investors
64.45% Public Companies and Individual Investors